본문으로 이동
BYO LUX
BYO LUXBe Your Own Luxury
치료 목록
Cosmetic

Restylane SHAYPE

High-G prime NASHA HD chin-shaping HA filler for skeletal lower-face support

시술 시간
20-40분
다운타임
1-7일
권장 횟수
通常1회+必要時タッチアップ (9-18개월ごと再評価)

이 치료에 대해

Restylane SHAYPE is a high-G prime hyaluronic acid filler built on Galderma’s NASHA HD technology and designed primarily for non-surgical correction of chin retrusion and lower-face skeletal support deficits. Compared with softer HA fillers, it is intended to provide stronger projection and structural support, allowing chin advancement, lower-face balance, and profile refinement with relatively small volumes.

Following approval in Canada in 2024, rollout in Brazil in 2025, and Galderma’s July 23, 2026 disclosure of a third approval in Thailand, it has become one of the more visible newer structural chin fillers in international injectables. Regional approval status remains uneven, so local market authorization must still be checked.

작용 기전

A dense, high-elasticity cross-linked HA gel is placed supraperiosteally or in deep soft tissue to provide forward projection and support in the mental region. NASHA HD is designed for high G-prime and shape retention, helping maintain contour support in the dynamic lower face, although depth, plane, and volume control are critical in the anatomically tight chin area.

적응증

처짐·윤곽일반 적응증(상세 설명 참고)

기대 효과

Product-specific randomized trials have shown meaningful improvement in chin retrusion and high naturalness ratings by Week 12 after a single treatment. A 2026 comparator trial also supported effectiveness and favorable safety versus Juvéderm Volux, reinforcing its role as a high-support filler capable of strong projection with modest volumes. Most patients are assessed after one session with optional touch-up.

임상 근거

제품 고유 / 동료심사
Nikolis A, Humphrey S, Rivers JK, et al. (2024)
Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. J Drugs Dermatol
해당 연구에서 임상적 개선이 보고되었습니다(자세한 내용은 원문 논문 참조).
제품 고유 / 동료심사
Nikolis A, Metelitsa A, Raco L, Safran T (2026)
Safety and Effectiveness of Two High-G' Soft Tissue Fillers for Chin Augmentation: A Prospective, Randomized, Comparator-Controlled, Evaluator-Blinded Trial. Aesthet Surg J
해당 연구에서 임상적 개선이 보고되었습니다(자세한 내용은 원문 논문 참조).
간접 근거 / 성분 클래스
Go BC, Frost AS, Friedman O (2023)
Using Injectable Fillers for Chin and Jawline Rejuvenation. World J Otorhinolaryngol Head Neck Surg
해당 연구에서 임상적 개선이 보고되었습니다(자세한 내용은 원문 논문 참조).
제조사 자료
Galderma (2026)
Galderma reports record first half 2026 net sales of 3.134 billion USD and 24.6% year-on-year growth at constant currency, raises net sales guidance for the full year. Manufacturer material
해당 연구에서 임상적 개선이 보고되었습니다(자세한 내용은 원문 논문 참조).

위험 및 부작용

Swelling, bruising, tenderness, firmness, asymmetry, and overcorrection may occur. The most important risk is vascular compromise, especially near the mental artery, submental artery, and adjacent lower-lip branches. Superficial placement can create visible irregularity or palpability, and because this is a deep-support filler, detailed anatomy knowledge and hyaluronidase readiness are essential.

이 치료에 관심이 있으신가요?

AI 피부 진단으로 현재 피부 상태를 확인해 보세요

AI 피부 진단 받기예약하기

다른 치료 보기

LaserPicoSure Pro자세히 보기 LaserFractional Laser자세히 보기 LaserPhotofacial IPL (Stellar M22)자세히 보기 Anti-AgingThermage FLX자세히 보기